Search research articles
Contact Us
Filters
Showing results (11-20 of 135) with videos related to
Page
of 14
Sort By:
Advances in Experimental Medicine and Biology
|
November 26, 2008
Compstatin: a complement inhibitor on its way to clinical application
Daniel Ricklin, John D Lambris
Seminars in Immunopathology
|
November 25, 2021
Complement & disease: out of the shadow into the spotlight
Daniel Ricklin, Richard B Pouw
Advances in Experimental Medicine and Biology
|
September 26, 2007
Exploring the complement interaction network using surface plasmon resonance
Daniel Ricklin, John D Lambris
Journal of Immunology (Baltimore, Md. : 1950)
|
April 9, 2013
Complement in immune and inflammatory disorders: pathophysiological mechanisms
Daniel Ricklin, John D Lambris
Seminars in Immunology
|
June 21, 2016
New milestones ahead in complement-targeted therapy
Daniel Ricklin, John D Lambris
Proceedings of the National Academy of Sciences of the United States of America
|
October 5, 2017
Complement-activation fragment C4a mediates effector functions by binding as untethered agonist to protease-activated receptors 1 and 4
HongBin Wang, Daniel Ricklin, John D Lambris
Molecular Immunology
|
October 6, 2009
Recent developments in low molecular weight complement inhibitors
Hongchang Qu, Daniel Ricklin, John D Lambris
Frontiers in Immunology
|
May 17, 2021
The Promiscuous Profile of Complement Receptor 3 in Ligand Binding, Immune Modulation, and Pathophysiology
Christina Lamers, Carla Johanna Plüss, Daniel Ricklin
Trends in Pharmacological Sciences
|
August 15, 2025
Danicopan: complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria
Ekaterina Umnyakova, Alexander J Lander, Daniel Ricklin
Immunobiology
|
September 12, 2012
The XXIV International Complement Workshop (ICW) on October 10-15, 2012. Preface
John D Lambris, George Hajishengallis, Daniel Ricklin
Page
of 14
Search research articles
Search
Showing results (11-20 of 135) with videos related to
Sort By:
Page
of 14
Advances in Experimental Medicine and Biology
|
November 26, 2008
Compstatin: a complement inhibitor on its way to clinical application
Daniel Ricklin, John D Lambris
Seminars in Immunopathology
|
November 25, 2021
Complement & disease: out of the shadow into the spotlight
Daniel Ricklin, Richard B Pouw
Advances in Experimental Medicine and Biology
|
September 26, 2007
Exploring the complement interaction network using surface plasmon resonance
Daniel Ricklin, John D Lambris
Journal of Immunology (Baltimore, Md. : 1950)
|
April 9, 2013
Complement in immune and inflammatory disorders: pathophysiological mechanisms
Daniel Ricklin, John D Lambris
Seminars in Immunology
|
June 21, 2016
New milestones ahead in complement-targeted therapy
Daniel Ricklin, John D Lambris
Proceedings of the National Academy of Sciences of the United States of America
|
October 5, 2017
Complement-activation fragment C4a mediates effector functions by binding as untethered agonist to protease-activated receptors 1 and 4
HongBin Wang, Daniel Ricklin, John D Lambris
Molecular Immunology
|
October 6, 2009
Recent developments in low molecular weight complement inhibitors
Hongchang Qu, Daniel Ricklin, John D Lambris
Frontiers in Immunology
|
May 17, 2021
The Promiscuous Profile of Complement Receptor 3 in Ligand Binding, Immune Modulation, and Pathophysiology
Christina Lamers, Carla Johanna Plüss, Daniel Ricklin
Trends in Pharmacological Sciences
|
August 15, 2025
Danicopan: complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria
Ekaterina Umnyakova, Alexander J Lander, Daniel Ricklin
Immunobiology
|
September 12, 2012
The XXIV International Complement Workshop (ICW) on October 10-15, 2012. Preface
John D Lambris, George Hajishengallis, Daniel Ricklin
Page
of 14